98 related articles for article (PubMed ID: 2573420)
1. Genetic alterations of c-myc, c-erbB-2, and c-Ha-ras protooncogenes and clinical associations in human breast carcinomas.
Garcia I; Dietrich PY; Aapro M; Vauthier G; Vadas L; Engel E
Cancer Res; 1989 Dec; 49(23):6675-9. PubMed ID: 2573420
[TBL] [Abstract][Full Text] [Related]
2. Oncogene amplification in squamous cell carcinoma of the oral cavity.
Saranath D; Panchal RG; Nair R; Mehta AR; Sanghavi V; Sumegi J; Klein G; Deo MG
Jpn J Cancer Res; 1989 May; 80(5):430-7. PubMed ID: 2502519
[TBL] [Abstract][Full Text] [Related]
3. Overexpression and amplification of the c-myc gene in mouse tumors induced by chemicals and radiations.
Niwa O; Enoki Y; Yokoro K
Jpn J Cancer Res; 1989 Mar; 80(3):212-8. PubMed ID: 2470712
[TBL] [Abstract][Full Text] [Related]
4. Integrative multi-omic sequencing reveals the MMTV-Myc mouse model mimics human breast cancer heterogeneity.
Broeker CD; Ortiz MMO; Murillo MS; Andrechek ER
Breast Cancer Res; 2023 Oct; 25(1):120. PubMed ID: 37805590
[TBL] [Abstract][Full Text] [Related]
5. Co-alteration of Myc and RTK-RAS pathways defines a liver-metastatic propensity and immune-cold subgroup of pancreatic adenocarcinoma.
Zhang Y; Zu Z; Xu H; Weng S; Ren Y; Cheng Q; Luo P; Zhang J; Liu Z; Han X
Genes Dis; 2024 May; 11(3):100993. PubMed ID: 38274372
[No Abstract] [Full Text] [Related]
6. The Predictive and Prognostic Role of RAS-RAF-MEK-ERK Pathway Alterations in Breast Cancer: Revision of the Literature and Comparison with the Analysis of Cancer Genomic Datasets.
Rocca A; Braga L; Volpe MC; Maiocchi S; Generali D
Cancers (Basel); 2022 Oct; 14(21):. PubMed ID: 36358725
[TBL] [Abstract][Full Text] [Related]
7. Magnetic resonance in the detection of breast cancers of different histological types.
Mayrhofer RM; Ng HP; Putti TC; Kuchel PW
Magn Reson Insights; 2013; 6():33-49. PubMed ID: 25114543
[TBL] [Abstract][Full Text] [Related]
8. Clinicopathological factors associated to HER-2 status in a hospital-based sample of breast cancer patients in Puerto Rico.
Ortiz AP; Frías O; González-Keelan C; Suárez E; Capó D; Pérez J; Cabanillas F; Mora E
P R Health Sci J; 2010 Sep; 29(3):265-71. PubMed ID: 20799514
[TBL] [Abstract][Full Text] [Related]
9. Frequency, prognostic impact, and subtype association of 8p12, 8q24, 11q13, 12p13, 17q12, and 20q13 amplifications in breast cancers.
Letessier A; Sircoulomb F; Ginestier C; Cervera N; Monville F; Gelsi-Boyer V; Esterni B; Geneix J; Finetti P; Zemmour C; Viens P; Charafe-Jauffret E; Jacquemier J; Birnbaum D; Chaffanet M
BMC Cancer; 2006 Oct; 6():245. PubMed ID: 17040570
[TBL] [Abstract][Full Text] [Related]
10. C-myc amplification in breast cancer: a meta-analysis of its occurrence and prognostic relevance.
Deming SL; Nass SJ; Dickson RB; Trock BJ
Br J Cancer; 2000 Dec; 83(12):1688-95. PubMed ID: 11104567
[TBL] [Abstract][Full Text] [Related]
11. Determination of c-myc amplification and overexpression in breast cancer patients: evaluation of its prognostic value against c-erbB-2, cathepsin-D and clinicopathological characteristics using univariate and multivariate analysis.
Scorilas A; Trangas T; Yotis J; Pateras C; Talieri M
Br J Cancer; 1999 Dec; 81(8):1385-91. PubMed ID: 10604737
[TBL] [Abstract][Full Text] [Related]
12. Molecular chemotherapy for breast cancer.
Patterson A; Harris AL
Drugs Aging; 1999 Feb; 14(2):75-90. PubMed ID: 10084362
[TBL] [Abstract][Full Text] [Related]
13. Classical gene amplifications in human breast cancer are not associated with distant solid metastases.
Driouch K; Champème MH; Beuzelin M; Bièche I; Lidereau R
Br J Cancer; 1997; 76(6):784-7. PubMed ID: 9310246
[TBL] [Abstract][Full Text] [Related]
14. FISH detection of HER-2/neu oncogene amplification in early onset breast cancer.
Xing WR; Gilchrist KW; Harris CP; Samson W; Meisner LF
Breast Cancer Res Treat; 1996; 39(2):203-12. PubMed ID: 8872329
[TBL] [Abstract][Full Text] [Related]
15. Transgenic mouse models of breast cancer.
Amundadottir LT; Merlino G; Dickson RB
Breast Cancer Res Treat; 1996; 39(1):119-35. PubMed ID: 8738611
[TBL] [Abstract][Full Text] [Related]
16. MCF10AT: a model for the evolution of cancer from proliferative breast disease.
Dawson PJ; Wolman SR; Tait L; Heppner GH; Miller FR
Am J Pathol; 1996 Jan; 148(1):313-9. PubMed ID: 8546221
[TBL] [Abstract][Full Text] [Related]
17. Critical determination of the frequency of c-erbB-2 amplification in breast cancer.
Hubbard AL; Doris CP; Thompson AM; Chetty U; Anderson TJ
Br J Cancer; 1994 Sep; 70(3):434-9. PubMed ID: 7915911
[TBL] [Abstract][Full Text] [Related]
18. Analysis of genetic alterations related to the development and progression of breast carcinoma.
Nagayama K; Watatani M
Jpn J Cancer Res; 1993 Nov; 84(11):1159-64. PubMed ID: 7903963
[TBL] [Abstract][Full Text] [Related]
19. Prognostic value of proliferating cell nuclear antigen and c-erbB-2 compared with conventional histopathological factors in breast cancer.
Schönborn I; Zschiesche W; Minguillon C; Spitzer E; Möhner M; Ebeling K; Grosse R
J Cancer Res Clin Oncol; 1995; 121(2):115-22. PubMed ID: 7883773
[TBL] [Abstract][Full Text] [Related]
20. ErbB-2 oncoprotein overexpression in breast carcinoma: inverse correlation with biochemically- and immunohistochemically-determined hormone receptors.
Keshgegian AA
Breast Cancer Res Treat; 1995 Aug; 35(2):201-10. PubMed ID: 7647342
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
